Integrative Molecular Profiling of Cervical Cancer Subtypes: Biomarkers, Molecular Pathways, and Precision Oncology Implications

Abstract

Cervical cancer remains one of the most prevalent malignancies affecting women globally, with a disproportionate burden in low-resource settings where screening and vaccination programs are limited. Persistent infection with high-risk human papillomavirus (HPV) strains is the primary etiological factor, leading to the expression of E6 and E7 oncoproteins that disrupt tumor suppressor pathways, including p53 and retinoblastoma protein, thereby promoting uncontrolled cell proliferation and genomic instability. Histologically, cervical cancer is classified into squamous cell carcinoma, adenocarcinoma, adenosquamous carcinoma, and neuroendocrine carcinoma, each exhibiting distinct molecular alterations. Squamous cell carcinoma, the most common subtype, is frequently associated with PIK3CA mutations, while adenocarcinomas demonstrate ERBB2 amplification and KRAS mutations. Rare subtypes such as adenosquamous and neuroendocrine carcinomas show mixed or aggressive molecular profiles. Key signaling pathways—including PI3K/AKT/mTOR, RAS/MAPK, Wnt/β-catenin, and JAK/STAT—contribute to tumor initiation, progression, and metastasis. Molecular biomarkers have become pivotal in clinical management: diagnostic markers such as p16^INK4a, HPV DNA, and E6/E7 mRNA facilitate early detection; prognostic markers, including TP53 mutations and Ki-67 proliferation index, inform disease outcome; and predictive markers like PD-L1 expression guide immunotherapy decisions. The integration of multi-omics approaches, encompassing genomics, transcriptomics, proteomics, and epigenomics, has enhanced tumor profiling, enabling the identification of novel therapeutic targets. These advances underpin precision medicine strategies, including PI3K inhibitors, immune checkpoint blockade, and anti-angiogenic therapies, aiming to improve treatment efficacy and minimize toxicity. Overall, cervical cancer is a molecularly heterogeneous disease, and combining histopathological classification with molecular characterization is critical for accurate diagnosis, risk stratification, and personalized therapy. Continued research into the molecular landscape of cervical cancer promises to advance targeted interventions and improve patient outcomes globally.